Background: Using the UK Cystic Fibrosis Database, we analysed the health of the UK CF paediatric population (UKPP) in terms of their biographical, clinical and infection status and compared outcomes with the US, French and Australasian CF Registries. Methods: UKPP data were collected for 2,673 patients aged less than 18 years in 2001 and used as a reference base for comparison with the most recent equivalent CF Registry reports. Results: Although differences exist between National CF Registries, all record similar demographic factors and key outcomes. Where plausible comparisons can be made, we report that the UKPP had the oldest median age (15.0 years), the Australasian population had the lowest median age at diagnosis (1.8 months). Approximately, double the expected number of UKPP patients (23% and 19%, respectively) fall below the 10th centile for height and weight with similar outcomes in Australasia. UKPP and French populations had similar proportions with FEV 1 >80% predicted (53% and 54%, respectively). Conclusion: Each Registry's data systems have developed independently providing a first step towards international comparisons. Standardisation of data collection criteria and definition for national CF Registries is required and we propose a standardised minimum data set, which would facilitate data integration as part of a global Registry for CF.
Introduction
Cystic Fibrosis (CF) is the commonest potentially lethal autosomal recessive disease in Caucasians. However, the health of individuals within a given CF population will be governed by the interaction between environmental factors such as different health care systems and clinical protocols [3] and their profile of genetic mutations [4] . Many countries have developed their own National Registries, following the formative impulse from the Canadian Patient Data Registry established in the mid 1960s [5] . These have led to a greater understanding of disease epidemiology and helped highlight important associations in disease progression [6] .
Differences in genetics and environment occur across continents and childhood death is now too infrequent to be used as an outcome. The aim of this study was to use the UK Cystic Fibrosis Database (UKCFD) to compare biographical, clinical and microbiological outcomes of the UK paediatric CF population with respect to the equivalent data reported from the US, French and Australasian CF Registries. While some useful comparisons can be made between the different CF populations, we propose the collection of minimum standard data fields to facilitate further future comparisons.
Methods
The UKCFD receives data from around 95% of specialist CF Centres and smaller clinics, as recently described [7] . A unique patient identifier is assigned to each patient following registration and submission of an initial patient biography to facilitate patient tracking across CF centres. These Fregistered_ patients are then flagged as Factive_ patients following submission of an annual clinical data return (Fig. 1) . The gap between the registered and active patients in Fig. 1 results from many factors: firstly, poorly staffed clinics outside the specialist CF centres are often unable to return clinical data even though their patients have undergone the one-off registration process, secondly, there is an approximate 2 year lead-time between the number of patients with complete clinical data compared with the number of registered patients (see Fig. 9 in Ref. [7] ) and thirdly, resourcing difficulties within CF centres lead to delayed returns. All CF Registries record similar demographic factors and key outcomes and we have concentrated on three quantitative outcomes: height, weight and pulmonary function and a qualitative marker predictive of severe disease: microbiological infection. Evidence of infection was accepted as the presence of the organism on at least one occasion whereas three or more isolates in a single year were regarded as evidence of chronic infection. Recent suggestions for changes to this definition were not available at the design stage of this work [8] . UKCFD data were analysed on 2673 Factive_ patients aged less than 18 years old in 2001 (Fig. 1) referred to as the UK paediatric patients (UKPP). Their outcomes were compared across continents with three equivalent paediatric populations in North America, Europe and the Southern Hemisphere, respectively within the US [9] , French [10] and Australasian [11] CF Registries.
The 2001 UKCFD data were compared with the most recent international CF Registry reports at that time. Although, we are cognisant of the important issues concerning data quality, selection bias and control of plausibility of data within Registries, these are outside the scope of this manuscript but are discussed later with reference to the plausibility of comparing outcomes between Registries. Within the UKCFD, computerised plausibility checks and manual measures are employed in error correction and range
Registered Patients = 6739
Age at diagnosis (months) 0 -2 3 -5 6 -8 9 -11 12+ Unknown % of 'active' pediatric population 0 checking to ensure validation of the data entry [7] . Similar measures are in place in the US Registry (Bruce Marshall, CFF, USA-personal communication). However, differences in data collection do exist and examples are given below. For the French and Australasian Registries, all non-biographical data compared for this study were recorded annually. Microbiology data from the French, Australasian and US Registries were recorded as per the UK on an ''ever cultured in the previous 12 months'' basis. Mean values for height, weight, body mass index (BMI) centiles and FEV 1 % predicted were calculated for each UK patient. Height, weight and FEV 1 recorded in the French Registry were those at the last visit or hospitalisation in the year 2000, while the highest FEV 1 in the year was recorded in the Australasian Registry. The US Registry records the occasion with the highest pulmonary function test results, height and/or weight (all obtained at the same clinic visit) for each quarter of the year. This may be relevant because daily intra-individual variation in lung function has been observed in CF patients, with poorer measurements recorded during acute exacerbations [12, 13] . However, the difference between mean recordings over a year and an annual highest recording has not been established. In the clinical experience of the authors, this can amount to 20% predicted FEV 1 . Clearly, categorical data quality for comparison between Registries can be more readily assured and will be less prone to variation than the collection and calculation of continuous data. Although we are not able to offer robust data plausibility and integrity from CF Registry publications other than our own, each Registries' output will be subject to the scrutiny and rigours of the Registry users.
Statistical analysis was performed using MINITAB version 13.1 (Minitab Inc, State College, Pennsylvania, USA), Excel 97 (Microsoft) and SPSS for Windows version 11.5 (SPSS Inc., Chicago, IL, USA). Graphical representations are presented using SigmaPlot (SigmaPlot for Windows version 4.01; SPSS Inc., Chicago, IL, USA). Differences between Registries were compared using the Mann -Whitney test (non-Gaussian distributed data), proportions analysis and chi-squared analysis [14] . All p values are two-sided. Fig. 1 shows that the UKCFD had 6739 registered (adult and paediatric) patients in 2001. This represents greater than 85% of the estimated UK CF population, projected to be 7910 in 2001 [15] ). Within this 6739 Fregistered_ population, 4689 were Factive_ having had an annual review in the preceding 12 months. This Factive_ population (median age 15 years; median age at diagnosis 4 months) contained 2673 Factive_ paediatric patients (PP) who formed a representative proportion of the 3945 Fregistered_ PP by comparison of median age and genetic profile (not shown). There was a small but significant difference between the percentage of DF508 homozygous patients in the Fregistered_ and Factive_ PP (55% versus 58%, respectively, p = 0.02). This possibly reflects a greater tendency towards Factive_ status amongst #F508/#F508 PP due to the increased severity of their disease [16] . However, as the proportions of #F508/other mutations were similar, this small excess in homozygous #F508 could still be a chance variation. The possible reasons for a registered patient not being included in the UKPP include shared care patients registered by a Specialist CF Centre but receiving clinical care at their local hospitals (with data not recorded for the UKCFD), patients who fail to receive an annual review, or patients who may be in transit between hospitals during the year in question. The impact of growth and nutrition on CF morbidity and mortality is well recognised [17 -19] , and our analysis of height and weight centiles (Figs. 2 and 3) demonstrated that approximately double the expected number of children (23% and 19%, respectively) lie below the 10th centiles. With respect to pulmonary status (Fig. 4) , almost half (47%) of the UKPP had an FEV 1 % predicted of < 80%. Table 1 shows the prevalence of bacterial airway infection in the UKPP stratified by age with the averaged prevalence shown in the last column. UKPP under 2 years of age are routinely treated with long-term flucloxacillin to prevent infection with Staphylococcus aureus, [20, 21] and 16% of these youngest patients have cultured S. aureus on at least one occasion. However, no patients had chronic S. aureus infection in this age group. In older age groups, the prevalence of chronic infection with S. aureus rose steeply until puberty. This contrasts with our finding that 6.8% of under 2-year-olds were chronically colonised with Pseudomonas aeruginosa, although this represents only a quarter of the children who had grown P. aeruginosa on at least one occasion during the year. Rates of Burkholderia complex (B. complex) were low, although there may be ascertainment bias through under-reporting as case identification is dependent on the proficiency of laboratory practices [22] . At present, the UKCFD does not record data on the nine genomovars included in the B. complex [23] . Haemophilus influenzae was recorded in over 30% of the UKPP less than 2 years of age although this prevalence fell with age to less than 15% of UKPP aged 15 -17.
Results
Having defined some key demographic and clinical outcomes in the UKPP, the similarities and differences with the US, French and Australasian Registries are discussed in the next Section (Tables 2 and 3 ).
Discussion
We have described the biographical, anthropometric and infection status of paediatric CF patients in the UK for 2001 using the UKCFD. These UKPP was compared with three paediatric CF populations reported by the US [9] , French [10] and Australasian [11] Registries. These were chosen to provide a pragmatic geographic spread and to illustrate the requirements for making valid international comparisons.
The UKCFD had the highest coverage of the four Registries analysed. Comparative analysis of coverage data indicated that each Registry was differentially representative of their respective total estimated population. The US population (of 280 million) had 22301 CF patients registered with the US Registry [9] . The coverage of US CF patients was estimated at 75% in 1993 [6] . The UK has around one fifth of the US population and the UKPP has approximately one fifth of the number of CF patients when compared to the US. The French Registry estimates patient coverage to be between 43 -59% [10] , and whilst the Australasian report does not indicate a specific figure and they acknowledge deficiencies in their adult patient coverage [11] due to data unavailability from some clinics (Dr. Scott Bell, Australasian Cystic Fibrosis Data Registrypersonal communication). However, the ''core'' demographic and diagnostic data for registered Australasian patients is more comprehensive than treatment and followup data [11] . This discrepancy is similar to Fregistered_ and Factive_ patients in the UKPP. Table 2 characterises each CF Registry population. The median age in the French and Australasian reports were lower than the 13.0 and 13.8 years attained in the UK and US, respectively. This may reflect ascertainment bias due to a lower coverage of the population. In the UK population, 67% of patients were diagnosed by 12 months of age, which is significantly lower than the 70% in the US ( p < 0.01), Australasian ( p < 0.05) and the 73% French values ( p < 0.01) [9 -11] . In the Australasian report, 94.3% of new patients in 2000 were diagnosed before 6 months of age, but only 70% of these were diagnosed through the neonatal screening programme [11] . Therefore, screening affected the median age at diagnosis as illustrated by comparing the Australasian population (1.8 months) with populations without full national screening (US-6 months, UK-4 months, France-4 months). Twenty percent of UK infants are already screened in restricted regional programmes with smaller proportions in the US and France. These observed differences in median age and age at diagnosis between countries may also be influenced by multiple factors other than screening. These may include national differences in paediatric surveillance systems, different data collection protocols across National Registries and incomplete coverage of Registry data for patients transferred to adult clinics. This area needs further study because it is presently controversial whether age at diagnosis is related to outcome [24] . Most clinical decisions in CF patient care are based on the interpretation of longitudinal trends in nutritional status, pulmonary function [25] and surveillance of microbiological infection. Even the apparently quantitative data on height, weight or pulmonary function are dependent on the use of appropriate reference equations [26] . But Registry reports do not always declare their specific reference equations for calculating height, weight and BMI centiles. These should be based on local populations to prevent the introduction of systematic bias (the reference equation used to calculate height, weight and BMI in the Australasian report was based on US reference data [11] ). While the US report did not list BMI data, the French reported gender-specific mean BMI plotted against age. The methods of calculating FEV 1 % predicted were referenced in the French and Australasian reports (but not the US) and were based on figures that may not reflect their respective populations [26, 27] . Reference populations will also vary between continents and races according to nutritional status [28] . Fifty-four percent of the French PP and 53% of the UKPP had FEV 1 % predicted > 80% (Fnormal_ lung function). It is reported that 37% of the Australasian population have Fnormal_ lung function, but their definition of Fnormal_ is not included. Comparison of US pulmonary function data with the French and Australasian reports was not possible because the US report uses the criterion of FEV 1 % predicted >90%, whilst the others use > 80%. Forty-two percent of the US population had FEV 1 % predicted > 90% and the equivalent UKPP proportion is much lower at 33%.
One parameter that should be readily comparable between Registries is the prevalence of common respiratory tract microbiological pathogens (Table 3) , but many difficulties remain. The acquisition of chronic P. aeruginosa is gradual and can lead to a slow deterioration in the patient's respiratory status, but remains a major factor in subsequent morbidity and mortality [29] . Some databases report single isolates of P. aeruginosa based on a single or multiple sampling throughout the year, but prevalence may be dependent on the frequency of sampling (i.e. patient contact with their CF team) [8] . The prevalence rates for P. aeruginosa were similar in the UKPP and US, but considerably higher than the rates in the French or Australasian populations. Differences in data definition and collection may have influenced this apparent difference [8] . We propose that documenting mucoid status as a surrogate for chronic infection may be simpler. Prevalence of infection with S. aureus increased with age in the UKPP, although this prevalence was significantly lower compared with equivalent US, French or Australasian data. This may represent the UK national policy to start oral prophylactic flucloxacillin in newly diagnosed UK CF infants [21] . Although the prevalence rates of patients isolating B. complex are low, our estimates suggest this organism leads to the segregation of 1 in 20 CF adolescents (aged 15-17 years) in the UK which has implications for longer-term psychological well-being [30] . Prevalence rates of B. complex are important because of its potentially transmissible nature and its impact on survival [31] . Prevalence was similar between reports, though significantly higher in the Australasian Registry than the UKPP in the 5 -17 age group, though in neither case did this rise above 5%. Although it is the commonest pathogen in CF during early childhood, rates of H. influenzae decreased with age in all populations. This may be explained by two factors: firstly, microbiology laboratories may only report what they regard as the primary pathogenic organism, which is less likely to be H. influenzae once the prevalence of S. aureus and P. aeruginosa increases (Professor J. Govan, Division of Medical Microbiology, University of Edinburgh-personal communication); secondly, cough swabs rather than sputum samples are more readily collected from younger infants who cannot yet expectorate and these could culture H. influenzae from the upper airway, which may or may not reflect lower airway infection [26, 32] . The French Registry reported a significantly higher prevalence of H. influenzae at all ages compared with the UKPP, although the UKPP had significantly higher prevalence rates at all ages compared with the US and Australasian reports (Table 3) . Whether the French prevalence reflects different treatment and reporting practice is unknown. Clearly, uniformity of data reporting would facilitate interpretation of these observed ''differences'', allowing the effect of different national management strategies to be further explored. Without standardised microbiological practice, this goal is likely to remain elusive.
The consequence of the individual development of each National Registry System has been an evolution of data collection methodology, analysis and presentation driven by the needs and demands of each Registry's CF community. At present, the Registries are of great value for comparisons within their individual populations, but present difficulties for comparisons between populations. This formulates the limitations on the control of data plausibility and leads to our case for a universal data collection strategy to facilitate future national comparisons. The functioning of the UKCFD requires an accurate definition of specific clinical outcomes in the UKPP and identification of areas where practice could be improved if resources permit. Having identified trends in the data between national databases we report a number of significant problems. There will be basic differences in the composition of the national CF populations in terms of ethnicity, genotype and screening [33, 34] . There are also likely to be systematic differences in data capture and patient coverage by the different national databases, and variations in how clinical data is recorded on these patients. A very important factor relates to differences in laboratory practice in isolating and reporting pathogenic organisms. Agreement must be reached on the definition of chronic microbiological infection across Registries [8] . Differences in recording practice for spirometry data may account for other variations, although the use of mean data over 12 months can overcome some of these problems. Most modern National Registries have only collected data for a few years, therefore longitudinal inferences can currently only be made using cross-sectional data. However, one of the longest running projects is the Canadian Patient Data Registry that has registered over 3400 patients (www.ccff.ca, accessed 01/01/05). These pioneering efforts have been a major influence on the development of other Registries and has reported on survival determinants and growth status and is regarded as an exemplar of Registry practice [5, 35] . Finally, differences in the format of the data presentation, including the omission of paediatric specific data, reduce the opportunity for comprehensive CF population comparisons. Considerable work has been done by the board of the European CF Registry towards specifying a standard EU CF Registry that will address these challenges. We outline in Table 4 our pragmatic proposal for common paediatric data, which would facilitate participation and initiate progress towards International Registry compatibility. This is envisaged as a two-stage process: all countries would contribute the essential demographics, whilst those countries in a position to contribute clinical data would provide these desirable fields in addition. This would require work towards defining national reference populations and age-appropriate formulae for nutritional and lung function data. Large International Registries (e.g. heart and lung transplantation [36, 37] ) have made successful comparisons of outcomes, and this should be a worthwhile goal for the CF Registries.
In conclusion, the development of national cystic fibrosis databases has enabled this comparison of the UKPP with the US, French and Australasian populations on selected key clinical outcomes. However, we have highlighted the limitations of comparing current national CF reports and recommend urgent standardisation of data collection between national CF Registries to facilitate greater understanding from intercontinental CF population comparisons.
